{"ticker": {"uuid": "b6bba957-a6f8-4063-a24a-8405a6b07abc", "symbol": "BBOT", "name": "BridgeBio Oncology Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to \"Sell\" Rating", "summary": "Wall Street Zen has upgraded BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a \"strong sell\" to a \"sell\" rating, while the overall analyst consensus remains a \"Moderate Buy\" with an average target price of $24.80. The company reported a significant loss per share for its lates", "url": "https://www.marketbeat.com/instant-alerts/bridgebio-oncology-therapeutics-nasdaqbbot-upgraded-by-wall-street-zen-to-sell-rating-2026-07-18/", "source_name": "MarketBeat", "published_at": "2026-07-18T06:14:04", "published_display": "18 Jul 2026 06:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment", "summary": "BridgeBio Oncology Therapeutics (BBOT) maintains a Buy rating despite a recent stock decline, due to its promising KRAS/RAS-targeted drug candidates. Key data readouts for its lead asset, BB-8520, which has shown strong efficacy in KRAS G12C NSCLC, are expected in the second half", "url": "https://seekingalpha.com/article/4921606-bridgebio-oncology-therapeutics-kras-program-data-2h26-may-reignite-bullish-sentiment", "source_name": "Seeking Alpha", "published_at": "2026-07-13T11:20:00", "published_display": "13 Jul 2026 11:20", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 7.9% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNa3FuMGFJbmJTb0t0V19hZko4SmlIN1BVUU95R3g1eUMxdUpuRFZMV1Vpa1g2NUwwcG5VZ1ZfMnlDcWpqX0xwUy0ybThQV3p3VVpHbjdPZTVWd2J4WVZ4NVkxOXJnX1JxYWdDSDhnR2NIZF9EbHNzVGhDOGZSbmZQVldCUnFLdHJaQTRuQi1JbXV3OWRteDE2YkVKMk9sdktNMEQtNlFGWkRzUnI0YTIxNUxGTmZHazJ2UGNTYnNwd0xKRDJWLU5v?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQR190T0p5bmpDNHcyOXU2aVJZS05uNTRlY01SeERNNUNPUFpHMk9Xa3plY3RFQ2czZEZGMG9scXNyQUJTaWZIOWVXeG96REtKWjBLRlAtaW82S0ZyWWJpcHFSYUppQUIyYVhZZHgtcnBDc2VkLWQ0NE4xWHFFYnAwWjNMX1c5dVJtQ3lSYkV5bUZlOVNJOFlBRGJuSVMyTVU4RTZKOWZUYlNlQUhZQ29rdnp3NG5DU1FzcjNuZl93?oc=5", "source_name": "TradingView", "published_at": "2026-07-08T16:28:00+00:00", "published_display": "08 Jul 2026 16:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates BridgeBio Oncology Therapeutics at Overweight", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-initiates-bridgebio-oncology-therapeutics-121402891.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:14:02+00:00", "published_display": "08 Jul 2026 12:14", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates BridgeBio Oncology stock with overweight rating", "summary": "JPMorgan initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00, citing the company's precision oncology approach. The stock, currently trading significantly below the target, has gained 6.3% recently. The ba", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-bridgebio-oncology-stock-with-overweight-rating-93CH-4780784", "source_name": "Investing.com", "published_at": "2026-07-08T12:40:35", "published_display": "08 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates BridgeBio Oncology stock with overweight rating By Investing.com", "summary": "JPMorgan initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00, citing significant upside potential from its current trading price of $8.29. The investment bank highlighted the company's precision oncology a", "url": "https://m.za.investing.com/news/stock-market-news/jpmorgan-initiates-bridgebio-oncology-stock-with-overweight-rating-93CH-4359753?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T08:10:51", "published_display": "08 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A BridgeBio Oncology Therapeutics For: 6 July By Investing.com", "summary": "This article reports that a Form 13D/A was filed for BridgeBio Oncology Therapeutics on July 6. The filing is a public disclosure related to significant ownership in a company. Further details of the filing are not included in this provided text.", "url": "https://in.investing.com/news/stock-market-news/form-13da-bridgebio-oncology-therapeutics-for-6-july-93CH-5484016", "source_name": "Investing.com India", "published_at": "2026-07-07T02:20:00", "published_display": "07 Jul 2026 02:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cormorant funds restructure 22.3% BridgeBio Oncology (BBOT) stake, add lock-up", "summary": "Cormorant-affiliated investors, led by Bihua Chen, have restructured their 22.32% beneficial ownership in BridgeBio Oncology Therapeutics (BBOT). This involved a pro rata distribution of 4,528,186 shares from Helix Holdings II LLC to other Cormorant funds (Fund III, Fund V, and M", "url": "https://www.stocktitan.net/sec-filings/BBOT/schedule-13d-a-bridge-bio-oncology-therapeutics-inc-amended-major-sha-5cee873403b8.html", "source_name": "Stock Titan", "published_at": "2026-07-07T00:11:52", "published_display": "07 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (BBOT) CMO uses 1,047 shares to cover RSU tax bill", "summary": "BridgeBio Oncology Therapeutics, Inc.'s Chief Medical & Development Officer, Ben Yong, had 1,047 shares of common stock withheld on July 1, 2026. This transaction covered tax obligations from vesting restricted stock units at a price of $7.80 per share, and was an automatic tax-w", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-cad7e17e33ed.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT (BBOT) COO Idan sees 343 shares withheld to cover RSU tax bill", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) COO & Principal Financial Officer Elmelech Idan had 343 shares of common stock withheld to cover tax obligations related to vesting restricted stock units. This was a non-open-market transaction for tax purposes, not a trade. Following", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-9c0e2594e134.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (NASDAQ: BBOT) officer reports tax-withheld RSU share disposition", "summary": "BridgeBio Oncology Therapeutics, Inc.'s Principal Accounting Officer, Marc Cobo, reported a disposition of 125 shares of Common Stock. This transaction was for tax withholding purposes in connection with the vesting of restricted stock units, not an open-market sale. Following th", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-61709762a4fe.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax withholding trims BridgeBio Oncology (BBOT) CEO Beltran\u2019s share count", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition, not an open-market sale, and Beltran no", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-80e59a1aaf89.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT SEC Filings - BridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms", "summary": "This article provides a comprehensive overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) SEC filings, including 10-K, 10-Q, and 8-K forms, catering to investors and traders. It details several recent filings such as a Q3 2025 loss and liquidity report, an 8-K announcing qua", "url": "https://www.stocktitan.net/sec-filings/BBOT/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-03T22:39:42", "published_display": "03 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) is highlighted as a promising cancer stock due to its differentiated oncology pipeline, particularly its KRAS-targeted programs like BBO-8520. Oppenheimer initiated coverage with an Outperform rating and a $22 price target, citing enco", "url": "https://finance.yahoo.com/markets/stocks/articles/bridgebio-oncology-therapeutics-inc-bbot-130619235.html", "source_name": "Market source", "published_at": "2026-06-30T13:06:00", "published_display": "30 Jun 2026 13:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for BridgeBio Oncology Therapeutics, Inc. (BBOT) stock based on analyst opinions. It details historical price performance, current market capitalization, and financial data such as recent earnings and revenue. The article also incl", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T13:40:58", "published_display": "29 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BridgeBio Oncology Therapeutics, Inc. \u2013 BOATS:BBOT", "summary": "This article provides a financial overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) on TradingView. It appears to be a stub or an incomplete data page, focusing on the \"Price to sales forward\" metric. The content indicates the market status as closed with no trades.", "url": "https://www.tradingview.com/symbols/BOATS-BBOT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:41:36", "published_display": "26 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BridgeBio Oncology Therapeutics, Inc. \u2013 NASDAQ:BBOT", "summary": "This article provides access to the \"Price to book forward\" financial metric for BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) through TradingView. It highlights the company's stock market presence on Nasdaq and confirms that the market was closed with no trades at the tim", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:41:36", "published_display": "26 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics, Inc. Actuals & Estimates (NASDAQ:BBOT)", "summary": "This article provides a financial overview and analyst estimates for BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT). It covers the company's current stock price, recent performance, analyst price targets, historical highs and lows, market capitalization, and upcoming earning", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:47", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Announces Target Price $22", "summary": "Oppenheimer has initiated coverage on BridgeBio Oncology Therapeutics (BBOT.US) with a Buy rating. The firm has set a target price of $22 for the company's stock.", "url": "https://www.moomoo.com/news/post/71826903/oppenheimer-initiates-bridgebio-oncology-therapeutics-bbotus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-23T08:09:42", "published_display": "23 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (BBOT) registers 63.05M shares for selling holders", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) has registered 63.05 million shares of Common Stock for resale by selling securityholders, as detailed in Prospectus Supplement No. 8 dated June 22, 2026. This supplement also includes governance items from the June 16, 2026 annual mee", "url": "https://www.stocktitan.net/sec-filings/BBOT/424b3-bridge-bio-oncology-therapeutics-inc-prospectus-filed-pursuant--ba4a2f0e9bdb.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:47", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michelle Doig resigns from BridgeBio Oncology Therapeutics board effective June 16, 2026", "summary": "Michelle Doig has resigned from the Board of Directors of BridgeBio Oncology Therapeutics (BBOT) upon completing her Class I term, effective June 16, 2026. Her resignation was not due to any disagreement with the company's operations, policies, or practices. The company has not d", "url": "https://www.tradingview.com/news/tradingview:cbf231934bb57:0-michelle-doig-resigns-from-bridgebio-oncology-therapeutics-board-effective-june-16-2026/", "source_name": "TradingView", "published_at": "2026-06-22T20:39:47", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (NASDAQ: BBOT) reports 2026 director elections and auditor ratification", "summary": "BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) reported the results of its June 16, 2026 Annual Meeting of Stockholders. Shareholders elected Peter Lebowitz and Frank P. McCormick as Class I directors and ratified the appointment of Deloitte & Touche LLP as the independent ", "url": "https://www.stocktitan.net/sec-filings/BBOT/8-k-bridge-bio-oncology-therapeutics-inc-reports-material-event-47b7d1277c2c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:47", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates BridgeBio Oncology stock rating at Outperform By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQMm5HQnd0Q2VRT1d5OS1Mek9jbHRGaFJiZUhvTVVyby00QXVPNmxoaGhFQm5oVkhYUXlhV2dwT2JFZm9WOUd2Zm82ZDUyN2pxY1VaWWFicU1jRmpQalJwUjZrX01FREM4XzdEQUF5VzRLZ19vUUZIZVU5eTdvQS1vUHJzVlF2UkstYTNkLV9iVFB1bFA0NFdWMTl0T2l3ZXFUOEVuYm9iVFZLWFVPU0szUzUtdlJaaXNKa0NDR183cDlHMFpHckNr?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics, Inc.(NasdaqGM:BBOT) added to S&P Biotechnology Select Industry Index", "summary": "BridgeBio Oncology Therapeutics, Inc. (NasdaqGM:BBOT) has been added to the S&P Biotechnology Select Industry Index. This news follows a series of recent updates for the company, including Q1 2026 financial results, inducement grants, and preclinical data presentations for its pi", "url": "https://www.marketscreener.com/news/bridgebio-oncology-therapeutics-inc-nasdaqgm-bbot-added-to-s-p-biotechnology-select-industry-inde-ce7f5cd3d88df322", "source_name": "www.marketscreener.com", "published_at": "2026-06-21T21:31:00", "published_display": "21 Jun 2026 21:31", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at BridgeBio Oncology (BBOT) receives 7,289 stock options", "summary": "A director at BridgeBio Oncology Therapeutics (BBOT), Peter F. Lebowitz, was granted 7,289 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Mee", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-ad0b32d73896.html", "source_name": "Stock Titan", "published_at": "2026-06-20T07:10:11", "published_display": "20 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at BridgeBio Oncology (BBOT) granted options for 31,675 shares", "summary": "BridgeBio Oncology Therapeutics director Praveen P. Tipirneni was granted stock options for 31,675 shares of Common Stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. They will vest fully on the earlier of the first anniversary of the grant ", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-4d9012641cc9.html", "source_name": "Stock Titan", "published_at": "2026-06-19T17:11:18", "published_display": "19 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chen Bihua, director, granted 31,675 options at BridgeBio Oncology (BBOT)", "summary": "BridgeBio Oncology Therapeutics (BBOT) director and 10% owner Chen Bihua was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. These options vest upon the earlier of the first anniversary of the grant date or the next Annual Meetin", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-0672c2cea5dc.html", "source_name": "Stock Titan", "published_at": "2026-06-19T16:40:33", "published_display": "19 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike", "summary": "BridgeBio Oncology Therapeutics director Raymond J. Kelleher was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual ", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-2534b89c22e8.html", "source_name": "Stock Titan", "published_at": "2026-06-19T06:11:22", "published_display": "19 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for BridgeBio Oncology Therapeutics Ord Shs (BBOT), highlighting analyst ratings and future growth estimates for EPS and Revenue. Based on ratings from 10 analysts, the stock currently has a \"Buy\" trend with a target price indicating a s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bbot/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:17", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence", "summary": "This article provides details on the institutional confidence in BridgeBio Oncology Therapeutics Ord Shs (BBOT). It lists key institutional shareholders, the number of shares held, and the percentage change in their holdings. The report highlights major investors like Cormorant A", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bbot/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:17", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of BridgeBio Oncology Therapeutics, Inc. \u2013 NASDAQ:BBOT", "summary": "This article provides financial information for BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) on TradingView. It displays shareholder data, though the specific values are not presented in the provided text. The page offers an overview of the company's financials, news, doc", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-16T16:08:46", "published_display": "16 Jun 2026 16:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)", "summary": "This article provides a technical analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) using various indicators like moving averages and oscillators. The analysis suggests a \"sell\" signal for BBOT stock, with stronger sell trends observed over a one-week period. It als", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/technicals/?utm_source=circlfi.com&utm_medium=widget_new&utm_campaign=technical-analysis", "source_name": "TradingView", "published_at": "2026-06-08T20:39:12", "published_display": "08 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026", "summary": "This article analyzes BridgeBio Oncology Therapeutics (BBOT) by comparing it to five competitors: DigitalBridge Group (DBRG), Four Corners Property Trust (FCPT), Uniti Group (UNIT), InvenTrust Properties (IVT), and Acadian Asset Management (AAMI). The comparisons cover various fa", "url": "https://www.marketbeat.com/stocks/NASDAQ/BBOT/competitors-and-alternatives/", "source_name": "MarketBeat", "published_at": "2026-05-26T07:09:01", "published_display": "26 May 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-reports-inducement-200500986.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution (NASDAQ:BBOT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOajI5UzlwN2hkRHpIQnp2YTR2bXJSLXRnMms5QnloOXpkX1hZdWFhQloySUVsX2ZueTdFMmNiNTNKQ0hHWWwwWmU1N01adjRXeE1kaG9MV0NUckJ6ejNDR1pXcC1zSU9ZblN0Wl9ZWkcya3p1X0JFU1dRSHQyVmUtLXhtZl9CTWhJUEFkdUlQNW9jby1VeENtOHNnZE5JV1ZyZTBOb0lYVkttQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA grants fast track status to BridgeBio\u2019s pancreatic cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQN0NkM3dzNURrYW5GeTlZaE1NNHFXX2hIYnFoTlRyRHNiYUszUFRXanJWc0lzQVhsQ0lPV1dJYnZqR3RsV1pndnlucTkxbVZlamdWWTRpVmQ5TzllZkdVNXpqWlU1R0pZeVZaRFptMG9JU3hDRHVTM0xpeFY0RmxSdU9uekRGb0c3cDlWTHM1QlVmXzRmWUozVDlEY1pndktpdUhkQkFmQzU4dFh3S3Ytd1ZhMWdUMG8weFdQMTllaw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOLVBMd0ZkeWdLdTl6UWN4bXg4NmJqYkVZekZtVTcyc0dOX1dJeFU1RGFRS29xY1oxRFhFb3FmS1hidzJ5eE0xeVp2Y0ZJbUtOWTFzdWhndFFCdDJMXzNvenZGY004NkhvSGFmU2dab0VDUE80WWpmVHZwbUVycFZRaGFDYnB5VDRRb1M0czdWUDQ?oc=5", "source_name": "Market source", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5mbDVMUmUxWGJTN1F5NDREb2dKY2NmQmFsbGdPRVF0aXROZTlfNC1DQUVpSG4tVUpaVDYySUhDemVHbUVPTDdwQ3VzRW95bFZxajBZQ0FDaUxjUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-16T01:24:12+00:00", "published_display": "16 Jan 2026 01:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVjhwNTJLOGprQnlUUnA0Vkluc2M1Z1MwMEdCSGNHeHIxdHlMcGNnOV9RS2FZZW81dmZTcFNQeklzOWxHUC1fX3pFVFppRjRObjJOV0tKN1dfSnotVWZaV1FBNl80cjY5TGczZzMybm03ekppTERGeVNqanBlVkdjQTRyaF8zalAtRW1vaGVGWHoxRjliSF8wbWVIWjRQTUlvcUxTV0pud3ZHZFI1b0ZybTNmUmVYdVdDeElnSXdKSnhOcUp6dm5F?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWFh4NWNhMEhKNW9VLTdHcTBXaDdfMmJmdkRhOC1aVFI4ME9IN29RNllQLW5uVzRPazNxTzR5Yktxa2kyWjJuVkZBM2JuajZ2eDQ3UmwyVmVpcHNoUnJ1bzRCOFJKUVp4LTkwRGFXb3V4X0dtM3RkaDNKNzBremNOa24xZGh4Mk1nXzI1SE81TmVhdG1ZN19nUXVVX3RkbmR5cExHaFA5M1Z2Y3ZFUDlfS1MyQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Rings the Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQcGJqMWNDcWZNV29GcHZ3cmFEZlFiNkhIMTVGSlBmci1qbVdVYm1QTTBVOGtuQUJSNkxtdmdncUpMR2NKa09tdm1KY2FMQzZSQ1c2N0NYSDNfVm1YSUd2VXU5dy1EbHkzVk9ma0hRRjFVcDZKOWxCV0QxNW55YTZXZi01ODJ3NVk?oc=5", "source_name": "Nasdaq", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNlhJMnRKN1kwdEJzMkh2Rnc2OTFrS2xaalhQLXFJbEhfd2FYVHlDcGdxaXg0eUVlOF9NYUh5UnF2eUtkQk40RDBaU1N3R2k4VW9VX1dVUEx4OVM3Yi1VaWtHZGxtdzNPVnEzVGEzWjJwLTFNcmhJZ2VKOUhwYlk0aGxZZEZ4MlN4ZkkwWGJOeklyMHVCZW1aSjJFLXBmaHpsb0FEXzRXdnZadC1wRkpacllKTlUwOEcxV1BsSGIwZTFHU25rc2RFLXlpdUdRR1hCQzBHaDdUQzhSTS10Z2QzS25XZ0tRS3NaeWh5UzBZQ2s4cDNLZEhVetIB_gFBVV95cUxQMDFlblZKRTExMHRRMXBoWkROdXU3T3YzV1hYb1VlSm1FT3F3c2xNbHZfNkFqc0o3MHBnazhuSWdhTUJMVzViYVMtdUEwMUJsbFBQbHJldjhDUWNqb1ZoWVFNOHZoVVhiQTQ1RzU3ZnZnYTJzTFgxaENSaEZqdTVGelVrYm5ZYVQwRndhTHJvN0Zvc2RkY2J5MVoyV2ttNmxTLVo1SjNzOS1mQ3lzMDd4Wnp2cFo3aFVCNjF2Yy1wZjk2UGpJM2JlZjFEaUlEYURQLVBsLVlQM2RjWGd5U3ZGV2N2dmVoTExPcndDaUl5cXNfNDA3dnZYVE1PYlVKUQ?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-17T07:00:00+00:00", "published_display": "17 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Inc (BBOT:UQ): Stock Price, Quote and News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE93WmlJanZxZjN3LTFNemYxcS15YlZtN1ZMeGsyVzNjQWZ6YUY2VVhJQnlGbHZwZnozaUMyeFVKZk01Uk1MUzRld1UxUG5EN2lsbjIwZg?oc=5", "source_name": "BNN Bloomberg", "published_at": "2025-08-14T23:23:20+00:00", "published_display": "14 Aug 2025 23:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy BridgeBio Oncology Therapeutics, Inc (BBOT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE53bHZaOXFPTFR1TlFCTDRDbC1fODRPXzdsUXc3OE01Vm5jOXMzR0pmX0IycG1OX183Qy0zYXQtS1Ita3I1dU1wdDJyU0ZNQ2E5NnNJcTQ0TUVna1BZVWJ2N25hbTBCRjFGeDhKcA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-14T03:51:54+00:00", "published_display": "14 Aug 2025 03:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT Stock Price and Chart \u2014 NASDAQ:BBOT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5BN0VhM2Z0WW00bTFydE1GOG1yZGQ1ckpHTTgxbmpKY2p6ci1sNk5hVjlWMDV1anhZTjI5SXdjcGtPS0x1WUd5ZEpvZTFGS0FvQi1RNmZxUkFoRnJM?oc=5", "source_name": "TradingView", "published_at": "2025-08-12T15:24:05+00:00", "published_display": "12 Aug 2025 15:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therape... (BBOT) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE40bFBLdnk1dDRzTW9hTVlmdU9Bc0xfWVhrOEMtQjNncmNrZm1KVl9MTENWZm1fVTFRejUzNEhZOWxja3RuWks1U2p0VWl3QQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-11T20:35:37+00:00", "published_display": "11 Aug 2025 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "White & Case advises Helix Acquisition Corp. II on its US$949 million business combination with BridgeBio Oncology Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPLTljbExOU0JLWU1TWlVqYzVqTVI5NEVfVlo4ZHpYb3Ewc1l5MjZ5Sk1HeS1EUVQ2dnBsRERGTk9TSDRiVlBsUVNDWDNpekR4OTFtM2ljSGRWaDc1UTRGNGVHSDI1U1pScWtvd21iaG1kVDdXQ2RzYUVwSENIUjVfXzdtZDZWTFBBeVFHNXRpY0ZEQzFqV2c0ZV9RZmpTUzR0eERDUUNENmFlYkM4REpmNzgtVkozQTA?oc=5", "source_name": "White & Case LLP", "published_at": "2025-03-03T08:00:00+00:00", "published_display": "03 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio oncology spinout to go public in blank-check merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQWRyT1JBR1hsMDRORXQxQnVkSVY4eElFVmFrSzliZFpKeUVubjhnSldHbHpMWkc5Wmo5VTh4c2Qyb3Q3TFp5dnkxeFVvZ2htRWo4c05fNWNDMDNSd3ZjZkZvTDQ4T2NyQUlCeTBuNjZrZGZ5Z19NcjJaTE9fY3dYMkl2aFN0Q2R3X2NJ?oc=5", "source_name": "BioPharma Dive", "published_at": "2025-02-28T08:00:00+00:00", "published_display": "28 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNdGlXXzBXYkFRM25HM2w1TnlNWUd0UV9CbnNzMUwyZVhrX0hKZ3dyTXJyN25WM0xjVE1DUHdGUVR5WWpGa0VRZVo5OUdLWFBSVDU0RU9Ld2RCNk9TUlRIcXdpS1VTZGo0TXJNVkNkd2Y0RWgwQ28waGt2Rlc5SzZoMHBET3Mwa01DOV9meVJnT0U4cnE1ZmdVcmNDbHo2QQ?oc=5", "source_name": "MedCity News", "published_at": "2025-02-28T08:00:00+00:00", "published_display": "28 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3K\u03b1-Targeting Medicines", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Business Wire", "published_at": "2025-02-28T08:00:00+00:00", "published_display": "28 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to \"Sell\" Rating", "summary": "Wall Street Zen has upgraded BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a \"strong sell\" to a \"sell\" rating, while the overall analyst consensus remains a \"Moderate Buy\" with an average target price of $24.80. The company reported a significant loss per share for its lates", "url": "https://www.marketbeat.com/instant-alerts/bridgebio-oncology-therapeutics-nasdaqbbot-upgraded-by-wall-street-zen-to-sell-rating-2026-07-18/", "source_name": "MarketBeat", "published_at": "2026-07-18T06:14:04", "published_display": "18 Jul 2026 06:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment", "summary": "BridgeBio Oncology Therapeutics (BBOT) maintains a Buy rating despite a recent stock decline, due to its promising KRAS/RAS-targeted drug candidates. Key data readouts for its lead asset, BB-8520, which has shown strong efficacy in KRAS G12C NSCLC, are expected in the second half", "url": "https://seekingalpha.com/article/4921606-bridgebio-oncology-therapeutics-kras-program-data-2h26-may-reignite-bullish-sentiment", "source_name": "Seeking Alpha", "published_at": "2026-07-13T11:20:00", "published_display": "13 Jul 2026 11:20", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 7.9% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNa3FuMGFJbmJTb0t0V19hZko4SmlIN1BVUU95R3g1eUMxdUpuRFZMV1Vpa1g2NUwwcG5VZ1ZfMnlDcWpqX0xwUy0ybThQV3p3VVpHbjdPZTVWd2J4WVZ4NVkxOXJnX1JxYWdDSDhnR2NIZF9EbHNzVGhDOGZSbmZQVldCUnFLdHJaQTRuQi1JbXV3OWRteDE2YkVKMk9sdktNMEQtNlFGWkRzUnI0YTIxNUxGTmZHazJ2UGNTYnNwd0xKRDJWLU5v?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQR190T0p5bmpDNHcyOXU2aVJZS05uNTRlY01SeERNNUNPUFpHMk9Xa3plY3RFQ2czZEZGMG9scXNyQUJTaWZIOWVXeG96REtKWjBLRlAtaW82S0ZyWWJpcHFSYUppQUIyYVhZZHgtcnBDc2VkLWQ0NE4xWHFFYnAwWjNMX1c5dVJtQ3lSYkV5bUZlOVNJOFlBRGJuSVMyTVU4RTZKOWZUYlNlQUhZQ29rdnp3NG5DU1FzcjNuZl93?oc=5", "source_name": "TradingView", "published_at": "2026-07-08T16:28:00+00:00", "published_display": "08 Jul 2026 16:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates BridgeBio Oncology Therapeutics at Overweight", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-initiates-bridgebio-oncology-therapeutics-121402891.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:14:02+00:00", "published_display": "08 Jul 2026 12:14", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates BridgeBio Oncology stock with overweight rating", "summary": "JPMorgan initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00, citing the company's precision oncology approach. The stock, currently trading significantly below the target, has gained 6.3% recently. The ba", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-bridgebio-oncology-stock-with-overweight-rating-93CH-4780784", "source_name": "Investing.com", "published_at": "2026-07-08T12:40:35", "published_display": "08 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates BridgeBio Oncology stock with overweight rating By Investing.com", "summary": "JPMorgan initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00, citing significant upside potential from its current trading price of $8.29. The investment bank highlighted the company's precision oncology a", "url": "https://m.za.investing.com/news/stock-market-news/jpmorgan-initiates-bridgebio-oncology-stock-with-overweight-rating-93CH-4359753?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T08:10:51", "published_display": "08 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A BridgeBio Oncology Therapeutics For: 6 July By Investing.com", "summary": "This article reports that a Form 13D/A was filed for BridgeBio Oncology Therapeutics on July 6. The filing is a public disclosure related to significant ownership in a company. Further details of the filing are not included in this provided text.", "url": "https://in.investing.com/news/stock-market-news/form-13da-bridgebio-oncology-therapeutics-for-6-july-93CH-5484016", "source_name": "Investing.com India", "published_at": "2026-07-07T02:20:00", "published_display": "07 Jul 2026 02:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cormorant funds restructure 22.3% BridgeBio Oncology (BBOT) stake, add lock-up", "summary": "Cormorant-affiliated investors, led by Bihua Chen, have restructured their 22.32% beneficial ownership in BridgeBio Oncology Therapeutics (BBOT). This involved a pro rata distribution of 4,528,186 shares from Helix Holdings II LLC to other Cormorant funds (Fund III, Fund V, and M", "url": "https://www.stocktitan.net/sec-filings/BBOT/schedule-13d-a-bridge-bio-oncology-therapeutics-inc-amended-major-sha-5cee873403b8.html", "source_name": "Stock Titan", "published_at": "2026-07-07T00:11:52", "published_display": "07 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (BBOT) CMO uses 1,047 shares to cover RSU tax bill", "summary": "BridgeBio Oncology Therapeutics, Inc.'s Chief Medical & Development Officer, Ben Yong, had 1,047 shares of common stock withheld on July 1, 2026. This transaction covered tax obligations from vesting restricted stock units at a price of $7.80 per share, and was an automatic tax-w", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-cad7e17e33ed.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT (BBOT) COO Idan sees 343 shares withheld to cover RSU tax bill", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) COO & Principal Financial Officer Elmelech Idan had 343 shares of common stock withheld to cover tax obligations related to vesting restricted stock units. This was a non-open-market transaction for tax purposes, not a trade. Following", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-9c0e2594e134.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (NASDAQ: BBOT) officer reports tax-withheld RSU share disposition", "summary": "BridgeBio Oncology Therapeutics, Inc.'s Principal Accounting Officer, Marc Cobo, reported a disposition of 125 shares of Common Stock. This transaction was for tax withholding purposes in connection with the vesting of restricted stock units, not an open-market sale. Following th", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-61709762a4fe.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax withholding trims BridgeBio Oncology (BBOT) CEO Beltran\u2019s share count", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition, not an open-market sale, and Beltran no", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-80e59a1aaf89.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:39:44", "published_display": "06 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT SEC Filings - BridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms", "summary": "This article provides a comprehensive overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) SEC filings, including 10-K, 10-Q, and 8-K forms, catering to investors and traders. It details several recent filings such as a Q3 2025 loss and liquidity report, an 8-K announcing qua", "url": "https://www.stocktitan.net/sec-filings/BBOT/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-03T22:39:42", "published_display": "03 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) is highlighted as a promising cancer stock due to its differentiated oncology pipeline, particularly its KRAS-targeted programs like BBO-8520. Oppenheimer initiated coverage with an Outperform rating and a $22 price target, citing enco", "url": "https://finance.yahoo.com/markets/stocks/articles/bridgebio-oncology-therapeutics-inc-bbot-130619235.html", "source_name": "Market source", "published_at": "2026-06-30T13:06:00", "published_display": "30 Jun 2026 13:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for BridgeBio Oncology Therapeutics, Inc. (BBOT) stock based on analyst opinions. It details historical price performance, current market capitalization, and financial data such as recent earnings and revenue. The article also incl", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T13:40:58", "published_display": "29 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BridgeBio Oncology Therapeutics, Inc. \u2013 BOATS:BBOT", "summary": "This article provides a financial overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) on TradingView. It appears to be a stub or an incomplete data page, focusing on the \"Price to sales forward\" metric. The content indicates the market status as closed with no trades.", "url": "https://www.tradingview.com/symbols/BOATS-BBOT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:41:36", "published_display": "26 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BridgeBio Oncology Therapeutics, Inc. \u2013 NASDAQ:BBOT", "summary": "This article provides access to the \"Price to book forward\" financial metric for BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) through TradingView. It highlights the company's stock market presence on Nasdaq and confirms that the market was closed with no trades at the tim", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:41:36", "published_display": "26 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics, Inc. Actuals & Estimates (NASDAQ:BBOT)", "summary": "This article provides a financial overview and analyst estimates for BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT). It covers the company's current stock price, recent performance, analyst price targets, historical highs and lows, market capitalization, and upcoming earning", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:47", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Announces Target Price $22", "summary": "Oppenheimer has initiated coverage on BridgeBio Oncology Therapeutics (BBOT.US) with a Buy rating. The firm has set a target price of $22 for the company's stock.", "url": "https://www.moomoo.com/news/post/71826903/oppenheimer-initiates-bridgebio-oncology-therapeutics-bbotus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-23T08:09:42", "published_display": "23 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (BBOT) registers 63.05M shares for selling holders", "summary": "BridgeBio Oncology Therapeutics, Inc. (BBOT) has registered 63.05 million shares of Common Stock for resale by selling securityholders, as detailed in Prospectus Supplement No. 8 dated June 22, 2026. This supplement also includes governance items from the June 16, 2026 annual mee", "url": "https://www.stocktitan.net/sec-filings/BBOT/424b3-bridge-bio-oncology-therapeutics-inc-prospectus-filed-pursuant--ba4a2f0e9bdb.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:47", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michelle Doig resigns from BridgeBio Oncology Therapeutics board effective June 16, 2026", "summary": "Michelle Doig has resigned from the Board of Directors of BridgeBio Oncology Therapeutics (BBOT) upon completing her Class I term, effective June 16, 2026. Her resignation was not due to any disagreement with the company's operations, policies, or practices. The company has not d", "url": "https://www.tradingview.com/news/tradingview:cbf231934bb57:0-michelle-doig-resigns-from-bridgebio-oncology-therapeutics-board-effective-june-16-2026/", "source_name": "TradingView", "published_at": "2026-06-22T20:39:47", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (NASDAQ: BBOT) reports 2026 director elections and auditor ratification", "summary": "BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) reported the results of its June 16, 2026 Annual Meeting of Stockholders. Shareholders elected Peter Lebowitz and Frank P. McCormick as Class I directors and ratified the appointment of Deloitte & Touche LLP as the independent ", "url": "https://www.stocktitan.net/sec-filings/BBOT/8-k-bridge-bio-oncology-therapeutics-inc-reports-material-event-47b7d1277c2c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:47", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates BridgeBio Oncology stock rating at Outperform By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQMm5HQnd0Q2VRT1d5OS1Mek9jbHRGaFJiZUhvTVVyby00QXVPNmxoaGhFQm5oVkhYUXlhV2dwT2JFZm9WOUd2Zm82ZDUyN2pxY1VaWWFicU1jRmpQalJwUjZrX01FREM4XzdEQUF5VzRLZ19vUUZIZVU5eTdvQS1vUHJzVlF2UkstYTNkLV9iVFB1bFA0NFdWMTl0T2l3ZXFUOEVuYm9iVFZLWFVPU0szUzUtdlJaaXNKa0NDR183cDlHMFpHckNr?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics, Inc.(NasdaqGM:BBOT) added to S&P Biotechnology Select Industry Index", "summary": "BridgeBio Oncology Therapeutics, Inc. (NasdaqGM:BBOT) has been added to the S&P Biotechnology Select Industry Index. This news follows a series of recent updates for the company, including Q1 2026 financial results, inducement grants, and preclinical data presentations for its pi", "url": "https://www.marketscreener.com/news/bridgebio-oncology-therapeutics-inc-nasdaqgm-bbot-added-to-s-p-biotechnology-select-industry-inde-ce7f5cd3d88df322", "source_name": "www.marketscreener.com", "published_at": "2026-06-21T21:31:00", "published_display": "21 Jun 2026 21:31", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at BridgeBio Oncology (BBOT) receives 7,289 stock options", "summary": "A director at BridgeBio Oncology Therapeutics (BBOT), Peter F. Lebowitz, was granted 7,289 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Mee", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-ad0b32d73896.html", "source_name": "Stock Titan", "published_at": "2026-06-20T07:10:11", "published_display": "20 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at BridgeBio Oncology (BBOT) granted options for 31,675 shares", "summary": "BridgeBio Oncology Therapeutics director Praveen P. Tipirneni was granted stock options for 31,675 shares of Common Stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. They will vest fully on the earlier of the first anniversary of the grant ", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-4d9012641cc9.html", "source_name": "Stock Titan", "published_at": "2026-06-19T17:11:18", "published_display": "19 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chen Bihua, director, granted 31,675 options at BridgeBio Oncology (BBOT)", "summary": "BridgeBio Oncology Therapeutics (BBOT) director and 10% owner Chen Bihua was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. These options vest upon the earlier of the first anniversary of the grant date or the next Annual Meetin", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-0672c2cea5dc.html", "source_name": "Stock Titan", "published_at": "2026-06-19T16:40:33", "published_display": "19 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike", "summary": "BridgeBio Oncology Therapeutics director Raymond J. Kelleher was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual ", "url": "https://www.stocktitan.net/sec-filings/BBOT/form-4-bridge-bio-oncology-therapeutics-inc-insider-trading-activity-2534b89c22e8.html", "source_name": "Stock Titan", "published_at": "2026-06-19T06:11:22", "published_display": "19 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for BridgeBio Oncology Therapeutics Ord Shs (BBOT), highlighting analyst ratings and future growth estimates for EPS and Revenue. Based on ratings from 10 analysts, the stock currently has a \"Buy\" trend with a target price indicating a s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bbot/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:17", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence", "summary": "This article provides details on the institutional confidence in BridgeBio Oncology Therapeutics Ord Shs (BBOT). It lists key institutional shareholders, the number of shares held, and the percentage change in their holdings. The report highlights major investors like Cormorant A", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bbot/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:17", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of BridgeBio Oncology Therapeutics, Inc. \u2013 NASDAQ:BBOT", "summary": "This article provides financial information for BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) on TradingView. It displays shareholder data, though the specific values are not presented in the provided text. The page offers an overview of the company's financials, news, doc", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-16T16:08:46", "published_display": "16 Jun 2026 16:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)", "summary": "This article provides a technical analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) using various indicators like moving averages and oscillators. The analysis suggests a \"sell\" signal for BBOT stock, with stronger sell trends observed over a one-week period. It als", "url": "https://www.tradingview.com/symbols/NASDAQ-BBOT/technicals/?utm_source=circlfi.com&utm_medium=widget_new&utm_campaign=technical-analysis", "source_name": "TradingView", "published_at": "2026-06-08T20:39:12", "published_display": "08 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026", "summary": "This article analyzes BridgeBio Oncology Therapeutics (BBOT) by comparing it to five competitors: DigitalBridge Group (DBRG), Four Corners Property Trust (FCPT), Uniti Group (UNIT), InvenTrust Properties (IVT), and Acadian Asset Management (AAMI). The comparisons cover various fa", "url": "https://www.marketbeat.com/stocks/NASDAQ/BBOT/competitors-and-alternatives/", "source_name": "MarketBeat", "published_at": "2026-05-26T07:09:01", "published_display": "26 May 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-reports-inducement-200500986.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution (NASDAQ:BBOT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOajI5UzlwN2hkRHpIQnp2YTR2bXJSLXRnMms5QnloOXpkX1hZdWFhQloySUVsX2ZueTdFMmNiNTNKQ0hHWWwwWmU1N01adjRXeE1kaG9MV0NUckJ6ejNDR1pXcC1zSU9ZblN0Wl9ZWkcya3p1X0JFU1dRSHQyVmUtLXhtZl9CTWhJUEFkdUlQNW9jby1VeENtOHNnZE5JV1ZyZTBOb0lYVkttQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants fast track status to BridgeBio\u2019s pancreatic cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQN0NkM3dzNURrYW5GeTlZaE1NNHFXX2hIYnFoTlRyRHNiYUszUFRXanJWc0lzQVhsQ0lPV1dJYnZqR3RsV1pndnlucTkxbVZlamdWWTRpVmQ5TzllZkdVNXpqWlU1R0pZeVZaRFptMG9JU3hDRHVTM0xpeFY0RmxSdU9uekRGb0c3cDlWTHM1QlVmXzRmWUozVDlEY1pndktpdUhkQkFmQzU4dFh3S3Ytd1ZhMWdUMG8weFdQMTllaw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOLVBMd0ZkeWdLdTl6UWN4bXg4NmJqYkVZekZtVTcyc0dOX1dJeFU1RGFRS29xY1oxRFhFb3FmS1hidzJ5eE0xeVp2Y0ZJbUtOWTFzdWhndFFCdDJMXzNvenZGY004NkhvSGFmU2dab0VDUE80WWpmVHZwbUVycFZRaGFDYnB5VDRRb1M0czdWUDQ?oc=5", "source_name": "Market source", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5mbDVMUmUxWGJTN1F5NDREb2dKY2NmQmFsbGdPRVF0aXROZTlfNC1DQUVpSG4tVUpaVDYySUhDemVHbUVPTDdwQ3VzRW95bFZxajBZQ0FDaUxjUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-16T01:24:12+00:00", "published_display": "16 Jan 2026 01:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVjhwNTJLOGprQnlUUnA0Vkluc2M1Z1MwMEdCSGNHeHIxdHlMcGNnOV9RS2FZZW81dmZTcFNQeklzOWxHUC1fX3pFVFppRjRObjJOV0tKN1dfSnotVWZaV1FBNl80cjY5TGczZzMybm03ekppTERGeVNqanBlVkdjQTRyaF8zalAtRW1vaGVGWHoxRjliSF8wbWVIWjRQTUlvcUxTV0pud3ZHZFI1b0ZybTNmUmVYdVdDeElnSXdKSnhOcUp6dm5F?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWFh4NWNhMEhKNW9VLTdHcTBXaDdfMmJmdkRhOC1aVFI4ME9IN29RNllQLW5uVzRPazNxTzR5Yktxa2kyWjJuVkZBM2JuajZ2eDQ3UmwyVmVpcHNoUnJ1bzRCOFJKUVp4LTkwRGFXb3V4X0dtM3RkaDNKNzBremNOa24xZGh4Mk1nXzI1SE81TmVhdG1ZN19nUXVVX3RkbmR5cExHaFA5M1Z2Y3ZFUDlfS1MyQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Rings the Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQcGJqMWNDcWZNV29GcHZ3cmFEZlFiNkhIMTVGSlBmci1qbVdVYm1QTTBVOGtuQUJSNkxtdmdncUpMR2NKa09tdm1KY2FMQzZSQ1c2N0NYSDNfVm1YSUd2VXU5dy1EbHkzVk9ma0hRRjFVcDZKOWxCV0QxNW55YTZXZi01ODJ3NVk?oc=5", "source_name": "Nasdaq", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNlhJMnRKN1kwdEJzMkh2Rnc2OTFrS2xaalhQLXFJbEhfd2FYVHlDcGdxaXg0eUVlOF9NYUh5UnF2eUtkQk40RDBaU1N3R2k4VW9VX1dVUEx4OVM3Yi1VaWtHZGxtdzNPVnEzVGEzWjJwLTFNcmhJZ2VKOUhwYlk0aGxZZEZ4MlN4ZkkwWGJOeklyMHVCZW1aSjJFLXBmaHpsb0FEXzRXdnZadC1wRkpacllKTlUwOEcxV1BsSGIwZTFHU25rc2RFLXlpdUdRR1hCQzBHaDdUQzhSTS10Z2QzS25XZ0tRS3NaeWh5UzBZQ2s4cDNLZEhVetIB_gFBVV95cUxQMDFlblZKRTExMHRRMXBoWkROdXU3T3YzV1hYb1VlSm1FT3F3c2xNbHZfNkFqc0o3MHBnazhuSWdhTUJMVzViYVMtdUEwMUJsbFBQbHJldjhDUWNqb1ZoWVFNOHZoVVhiQTQ1RzU3ZnZnYTJzTFgxaENSaEZqdTVGelVrYm5ZYVQwRndhTHJvN0Zvc2RkY2J5MVoyV2ttNmxTLVo1SjNzOS1mQ3lzMDd4Wnp2cFo3aFVCNjF2Yy1wZjk2UGpJM2JlZjFEaUlEYURQLVBsLVlQM2RjWGd5U3ZGV2N2dmVoTExPcndDaUl5cXNfNDA3dnZYVE1PYlVKUQ?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-17T07:00:00+00:00", "published_display": "17 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics Inc (BBOT:UQ): Stock Price, Quote and News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE93WmlJanZxZjN3LTFNemYxcS15YlZtN1ZMeGsyVzNjQWZ6YUY2VVhJQnlGbHZwZnozaUMyeFVKZk01Uk1MUzRld1UxUG5EN2lsbjIwZg?oc=5", "source_name": "BNN Bloomberg", "published_at": "2025-08-14T23:23:20+00:00", "published_display": "14 Aug 2025 23:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy BridgeBio Oncology Therapeutics, Inc (BBOT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE53bHZaOXFPTFR1TlFCTDRDbC1fODRPXzdsUXc3OE01Vm5jOXMzR0pmX0IycG1OX183Qy0zYXQtS1Ita3I1dU1wdDJyU0ZNQ2E5NnNJcTQ0TUVna1BZVWJ2N25hbTBCRjFGeDhKcA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-14T03:51:54+00:00", "published_display": "14 Aug 2025 03:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBOT Stock Price and Chart \u2014 NASDAQ:BBOT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5BN0VhM2Z0WW00bTFydE1GOG1yZGQ1ckpHTTgxbmpKY2p6ci1sNk5hVjlWMDV1anhZTjI5SXdjcGtPS0x1WUd5ZEpvZTFGS0FvQi1RNmZxUkFoRnJM?oc=5", "source_name": "TradingView", "published_at": "2025-08-12T15:24:05+00:00", "published_display": "12 Aug 2025 15:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therape... (BBOT) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE40bFBLdnk1dDRzTW9hTVlmdU9Bc0xfWVhrOEMtQjNncmNrZm1KVl9MTENWZm1fVTFRejUzNEhZOWxja3RuWks1U2p0VWl3QQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-11T20:35:37+00:00", "published_display": "11 Aug 2025 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "White & Case advises Helix Acquisition Corp. II on its US$949 million business combination with BridgeBio Oncology Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPLTljbExOU0JLWU1TWlVqYzVqTVI5NEVfVlo4ZHpYb3Ewc1l5MjZ5Sk1HeS1EUVQ2dnBsRERGTk9TSDRiVlBsUVNDWDNpekR4OTFtM2ljSGRWaDc1UTRGNGVHSDI1U1pScWtvd21iaG1kVDdXQ2RzYUVwSENIUjVfXzdtZDZWTFBBeVFHNXRpY0ZEQzFqV2c0ZV9RZmpTUzR0eERDUUNENmFlYkM4REpmNzgtVkozQTA?oc=5", "source_name": "White & Case LLP", "published_at": "2025-03-03T08:00:00+00:00", "published_display": "03 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio oncology spinout to go public in blank-check merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQWRyT1JBR1hsMDRORXQxQnVkSVY4eElFVmFrSzliZFpKeUVubjhnSldHbHpMWkc5Wmo5VTh4c2Qyb3Q3TFp5dnkxeFVvZ2htRWo4c05fNWNDMDNSd3ZjZkZvTDQ4T2NyQUlCeTBuNjZrZGZ5Z19NcjJaTE9fY3dYMkl2aFN0Q2R3X2NJ?oc=5", "source_name": "BioPharma Dive", "published_at": "2025-02-28T08:00:00+00:00", "published_display": "28 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNdGlXXzBXYkFRM25HM2w1TnlNWUd0UV9CbnNzMUwyZVhrX0hKZ3dyTXJyN25WM0xjVE1DUHdGUVR5WWpGa0VRZVo5OUdLWFBSVDU0RU9Ld2RCNk9TUlRIcXdpS1VTZGo0TXJNVkNkd2Y0RWgwQ28waGt2Rlc5SzZoMHBET3Mwa01DOV9meVJnT0U4cnE1ZmdVcmNDbHo2QQ?oc=5", "source_name": "MedCity News", "published_at": "2025-02-28T08:00:00+00:00", "published_display": "28 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3K\u03b1-Targeting Medicines", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Business Wire", "published_at": "2025-02-28T08:00:00+00:00", "published_display": "28 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 61, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 42, "score": 55, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 19.0, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 5.3, "count": 9}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 8.56, "latest_week": "2026-07-17", "one_week_move": 2.9, "four_week_move": 13.2, "twelve_week_move": -2.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.028442, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -16.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.7815, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.9% over one week, +13.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 8}, {"label": "MarketBeat", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 9}, {"label": "Deals and strategy", "count": 6}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.9% over one week, +13.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to \"Sell\" Rating"}], "updated_at": "2026-07-21T00:51:25.858184+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}